Beyond Binders: High-Throughput Peptide Screening for Functionally Active Hits
Sally Wang Liang
SVP of BD, PepLib
PepLib is rethinking peptide drug discovery beyond binders to functionally active hits. PepLib’s novel peptide technology platform uses 80-mer cyclic peptides to encode and compress half of a billion sequences, including complete peptide libraries up to pentapeptides (ZSenithFive™). PepLib’s platform, powered by Peptide Information Compression Technology (PICT), is capable of high-sensitivity and high-specificity drug mining for a broad spectrum of targets, including membrane-proteins, such as GPCR and ion channels, peptide drug conjugates, and directly on cell-lines. Intelligently designed, individually isolated and packed peptides in HTS compatible format breaks through traditional limitations of peptide screening platforms, extending capabilities beyond binding assays to biochemical and cell-based functional assay. PepLib has validated the efficiency of the platform in over 40 successful screenings on dozens of molecular targets and cell-lines, through external partnerships with leading global (e.g., AstraZeneca) and Chinese pharmaceutical companies, and robust internal development programs, across multiple therapeutic areas. Founded by top scientists in peptide chemistry and biosynthesis, PepLib hopes to leverage its innovative platform to advance peptide drug discovery for the global biopharmaceutical community.